Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-BGB-11417 in Healthy Male Subjects
NCT05844111Phase 1Completed
- Sponsor
- BeiGene
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonrotoclax in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL), sponsored by BeiGene. Primary endpoints: Area under the concentration curve from time 0 to the last quantifiable concentration, Maximum concentration of BGB-11417 in Plasma and 5 more. Started May 2023; status: completed.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05844111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844111.